• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients.
CONCLUSIONS: There was a high rate of symptomatic response to antithrombotic therapy in this context and long-term follow up suggested an individualized symptom-derived antithrombotic regimen may be associated with a low bleeding risk. Our data support consideration of a 2-4 week trial of antithrombotic therapy, usually starting with antiplatelet therapy, in aPL-positive patients with refractory migraine, particularly if other treatment options have been exhausted. As a retrospective study, our data provide only Class IV level of evidence, but they suggest randomized controlled trials are warranted to validate these enco...
Source: Lupus - January 5, 2021 Category: Rheumatology Authors: Schofield JR, Hughes HN, Birlea M, Hassell KL Tags: Lupus Source Type: research

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab
Publication date: Available online 2 December 2015 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sara Khodor, Miguel Castro, Colin McNamara, Chakra P. Chaulagain Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the development of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ t...
Source: Hematology Oncology and Stem Cell Therapy - March 7, 2016 Category: Cancer & Oncology Source Type: research